UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 29, 2006
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
000-21214
|
|
86-0585310 |
|
|
|
|
|
|
| (State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer |
| of incorporation)
|
|
|
|
Identification No.) |
| |
|
|
|
| 1275 West Washington Street, Tempe, Arizona
|
|
85281 |
|
|
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
|
Registrant’s telephone number, including area code:
(602) 286-5520
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Section 8 — Other Events
Item 8.01 Other Events
On August 29, 2006, OrthoLogic Corp. announced by press release the results of preliminary
interim analysis of data from its Phase 2b dose-ranging clinical trial of the novel synthetic
peptide Chrysalin® (TP508) in unstable, displaced distal radius (wrist) fractures and
termination of the Phase 2b study. In the dataset of 240 subjects as a group that were evaluable in
the Phase 2b interim analysis, treatment with Chrysalin did not demonstrate benefit compared to
placebo in the primary efficacy endpoint of time to removal of immobilization. Individual findings
of efficacy in secondary endpoints, including radiographic healing, were not seen in this interim
analysis. Further, no dose response relationship was observed. The trial met the pre-specified
safety endpoint by demonstrating no significant difference in the incidence of adverse events
between the Chrysalin and placebo groups. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated by reference herein.